DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis

详细信息	查看全文 | 推荐本文 |

• 作者：Jindrich Soltys^a ; ^{jsoltys@slu.edu} ; Jose A. Halperin^b ; ^c ; Qin Xuebin^b ; ^c
• 关键词：Acetylcholine receptor (AChR) ; Experimental autoimmune myasthenia gravis (EAMG) ; Regulators of complement activity (RCA) ; Decay accelerating factor (DAF/CD55) ; Protectin (CD59) ; Humoral and adaptive immune response
• 刊名：Journal of Neuroimmunology
• 出版年：2012
• 期刊代码：32_01655728
• 类别：neu
• 出版时间：March, 2012
• 卷：244
• 期：1-2
• 页码：63-69
• 文件大小：860 K

摘要

The role of regulators of complement activity (RCA) involving CD55 and CD59 in the pathogenesis of experimental autoimmune myasthenia gravis (EAMG) remains unclear. CD55 and CD59 restrict complement activation by inhibiting C3/C5 convertases' activities and membrane attack complex formation, respectively. Actively immunized EAMG mice deficient in either CD55 or CD59 showed significant differences in adaptive immune responses and worsened disease outcome associated with increased levels of serum cytokines, modified production of acetylcholine receptor antibodies, and more complement deposition at the neuromuscular junction. We conclude that modulation of complement activity by RCA represents an alternative in controlling of autoimmune processes in EAMG.